Latest Renal cell carcinoma Stories
EAST HANOVER, N.J., June 5 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that results from a Phase II study show AfinitorÂ® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS) (1,2).
CHICAGO, June 4 /PRNewswire-FirstCall/ -- Genomic Health, Inc.
ABBOTT PARK, Ill., June 3 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) scientists and independent researchers will highlight the latest clinical trial data on four of Abbott's investigational oncology compounds at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 4-8 in Chicago.
EAST HANOVER, N.J., June 3 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that a Phase III study of AfinitorÂ® (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors (NET).
A minimally invasive technique used to destroy kidney tumors with an electrically controlled heating probe showed similar effectiveness as surgical removal of tumors in curbing cancer recurrence rates for up to five years after treatment.
When kidney cancer spreads to other body parts, patients usually receive a poor prognosis.
Kidney cancer is a radiographic diagnosis which means treatment decisions are often made based on the findings of a solid mass on CT or MRI.
SAN DIEGO, June 2 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced that it will report new data on its proprietary oncology diagnostic platform, a novel technology that forms the basis of the Company's recently announced collaboration with Bayer Schering Pharma AG.
Fox Chase Cancer Center researchers will present three abstracts at the 2010 annual meeting of the American Urological Association (AUA) that demonstrate progress in the use of the R.E.N.A.L. Nephrometry Scoring to characterize renal mass anatomy and allow standardization of surgical decision-making and comparison of outcomes in patients with kidney cancers.
Small but decisive study highlights differences in clear- and non-clear cell subtypes.
- To say in too many words; to express verbosely.
- To express in too many words: sometimes used reflexively.
- The leading idea or a repeated phrase, as of a song or ballad; the refrain; burden.